No-Reflow Phenomenon During Percutaneous Coronary Intervention: Prevention and Treatment

Definition and Pathophysiology

No-reflow is impaired anterograde myocardial perfusion despite the absence of a flow-limiting epicardial coronary stenosis. It is therefore a disorder of coronary microvascular perfusion rather than persistent obstruction of the treated epicardial segment.

The phenomenon occurs in approximately 2%–3% of PCI procedures overall. It is particularly associated with intervention on degenerated saphenous vein grafts (SVGs), rotational atherectomy, and procedures performed for acute myocardial infarction. In SVG-PCI, slow-flow or no-reflow rates may reach 15%–20%, substantially exceeding those seen with native-vessel PCI.

Mechanisms

The principal mechanism is distal embolization of atheromatous and thrombotic material. Plaque or thrombus may be dislodged by:

• Balloon inflation

• Atherectomy

• Stent implantation

• Manipulation of friable SVG lesions

Embolic debris obstructs the distal microcirculation and may be accompanied by microvascular constriction and endothelial or myocardial injury. Antithrombotic therapy may reduce embolization of thrombotic or atheroembolic material, but pharmacological and mechanical strategies directed specifically at reperfusion injury have not generally demonstrated sufficient clinical benefit for routine use.

No-reflow may also occur in association with other procedural complications, including distal embolization, coronary dissection, perforation, and abrupt closure. The clinical consequences depend heavily on the amount of viable myocardium supplied by the affected artery. Large areas of jeopardized myocardium, severe baseline stenosis, multivessel coronary artery disease, and diffuse disease increase the likelihood of cardiovascular collapse when PCI fails or flow is severely compromised.

Clinical Presentation

No-reflow may become apparent during or immediately after PCI. The clinical presentation depends on the extent of microvascular obstruction and the territory supplied by the treated vessel.

Possible manifestations include:

• Persistent or recurrent myocardial ischemia

• Deterioration in ventricular function

• Hemodynamic instability

• Periprocedural myocardial infarction

• Cardiogenic shock

• Cardiac arrest

The severity may be disproportionate to the angiographic appearance of the treated epicardial artery, because the defining abnormality is inadequate distal perfusion in the absence of a major residual epicardial obstruction.

No-reflow is associated with serious short- and long-term outcomes. Its occurrence is associated with an approximately fivefold higher risk of periprocedural MI and a threefold higher risk of death.

Evaluation and Procedural Recognition

Recognition is primarily angiographic and clinical. No-reflow should be suspected when distal coronary perfusion remains reduced despite successful treatment of the apparent epicardial stenosis and without an angiographically evident flow-limiting obstruction.

Assessment should include:

• Confirmation that the treated epicardial segment is adequately expanded and not severely obstructed.

• Exclusion of coronary dissection compromising the true lumen.

• Assessment for thrombus, distal embolization, abrupt closure, or perforation.

• Evaluation of distal flow and myocardial perfusion.

• Continuous assessment of ischemia, ventricular function, blood pressure, and signs of shock.

A coronary dissection that extends into the media or adventitia can compromise the true lumen and cause ischemia. Guiding-catheter trauma is an additional mechanism of dissection and impaired distal flow. These alternative causes must be distinguished from isolated no-reflow because their treatment may require immediate stenting or other procedural intervention.

The clinical importance of the finding is related to the extent of myocardium at risk. Occlusion or impaired perfusion in a vessel supplying a large viable territory is more likely to produce rapid hemodynamic deterioration than a similar angiographic abnormality involving a smaller territory.

Diagnostics

Coronary Angiography

Angiography is the central diagnostic modality during PCI. No-reflow is identified by reduced anterograde perfusion despite the absence of a flow-limiting stenosis.

Angiographic assessment should determine whether there is:

• Adequate restoration of the epicardial lumen

• Persistent distal underperfusion

• Distal embolization

• Slow flow

• Residual dissection

• Stent-related obstruction

• Coronary perforation

The phenomenon may occur after otherwise technically successful PCI. In SVG intervention, the high plaque burden and friability of the graft lesion create particular susceptibility to embolization and distal microvascular obstruction.

Intravascular and Adjunctive Imaging

The source material does not provide specific recommendations regarding intravascular ultrasound, optical coherence tomography, or other imaging methods for diagnosing or managing no-reflow. Optical coherence tomography is described as useful for detecting neoatherosclerosis after stent implantation, but this is a late stent-related process rather than a diagnostic strategy for acute no-reflow.

Electrocardiography and Echocardiography

The source material does not specify ECG criteria, echocardiographic findings, or formal non-invasive diagnostic pathways for no-reflow. Clinically, the condition should nevertheless be considered in the setting of persistent ischemia or hemodynamic deterioration despite restoration of the epicardial lumen.

Biomarkers and Laboratory Findings

Specific biomarker thresholds or laboratory criteria for no-reflow are not provided. Because no-reflow is associated with a markedly increased risk of periprocedural MI, serial assessment for myocardial injury may be clinically relevant, but the source material does not define particular biomarker values or testing schedules.

Renal function is important when selecting a revascularization strategy in patients with STEMI and multivessel disease. In cardiogenic shock, immediate multivessel PCI increases the risk of death or renal replacement therapy compared with culprit-only PCI. This consideration relates to procedural strategy rather than serving as a diagnostic marker of no-reflow.

Prevention

Prevention is directed toward limiting distal embolization, avoiding unnecessary vessel trauma, and selecting an appropriate procedural strategy.

Lesion and Device Considerations

Risk is increased in:

• Degenerated SVGs

• Lesions with extensive and friable plaque burden

• Rotational atherectomy

• Acute myocardial infarction interventions

• Procedures involving a large territory of jeopardized myocardium

In SVG-PCI, strategies that may reduce slow-flow and no-reflow include:

• Direct stenting rather than routine predilation

• Appropriate stent sizing, with avoidance of oversizing

• Use of embolic protection devices when feasible

Embolic protection devices are recommended as class I in the 2011 ACC/AHA PCI guidelines and as class IIa in the 2018 ESC/EACTS guidelines for SVG-PCI.

Access Strategy

Radial access is preferred for PCI in acute coronary syndromes because it reduces bleeding and vascular complications compared with femoral access and is associated with lower mortality. This is an overall procedural safety recommendation rather than a specific treatment for no-reflow, but it is relevant to the management of high-risk PCI.

Antithrombotic Therapy

Patients with acute STEMI should receive anticoagulant and antiplatelet therapy. The specific agents and duration depend on:

• The reperfusion strategy

• Ischaemic risk

• Bleeding risk

• Comorbidities

• The presence of an independent indication for long-term anticoagulation, such as atrial fibrillation

Antithrombotic treatment may help limit thrombotic embolization and maintain microvascular integrity. However, the source material does not provide a specific antithrombotic regimen or dosing schedule for prevention of no-reflow.

Aspiration Thrombectomy

Routine aspiration thrombectomy before primary PCI is not recommended. It carries a class III recommendation because trials showed no improvement in cardiovascular outcomes and suggested a possible increase in stroke risk.

Reperfusion Injury Strategies

A number of interventions have been investigated to reduce reperfusion injury, including modulation of vasodilation, inflammation, mitochondrial permeability, and cellular protective pathways. Except for antithrombotic treatment, these approaches are not recommended for routine clinical practice on the basis of the evidence presented.

Remote ischaemic conditioning and postconditioning have produced inconsistent results. Remote conditioning did not reduce cardiovascular death or hospitalization for heart failure in a large STEMI primary-PCI study, and clinical data do not support routine adoption of either strategy.

Treatment

Immediate Principles

Once no-reflow is recognized, management should proceed urgently because severe consequences can develop rapidly. The immediate priorities are:

• Confirm the diagnosis angiographically.

• Exclude and correct mechanical causes of impaired flow.

• Assess the size of the jeopardized myocardial territory.

• Monitor for ischaemia, ventricular failure, and shock.

• Administer an intracoronary vasodilator when appropriate.

• Provide haemodynamic and circulatory support if deterioration occurs.

Exclusion of Mechanical Causes

No-reflow should not be diagnosed until important epicardial causes of impaired perfusion have been considered. These include:

• Residual or flow-limiting dissection

• Guiding-catheter-induced dissection

• Stent-related obstruction

• Distal embolization

• Coronary perforation

• Abrupt vessel closure

Significant residual dissection of the treated artery is associated with increased risks of postprocedural MI, emergency CABG, stent thrombosis, and mortality. Prompt stenting can treat most intra-procedural dissections, although the appropriate intervention depends on the anatomy and the extent of true-lumen compromise.

Coronary perforation is uncommon, occurring in approximately 0.2%–0.5% of PCI procedures, but it may cause tamponade and haemodynamic collapse within minutes. A deteriorating patient with impaired coronary flow therefore requires assessment for perforation as well as no-reflow.

Intracoronary Vasodilators

When no-reflow occurs, arterial vasodilators may be administered into the affected vessel, particularly in SVG-PCI. Agents described include:

• Sodium nitroprusside

• Verapamil

• Adenosine

These drugs may improve flow into the distal native coronary circulation. However, although flow may improve angiographically, the risk of death or MI remains substantially increased. The efficacy of pharmacological treatment in reducing subsequent adverse clinical events remains uncertain.

No specific doses are provided in the source material.

Saphenous Vein Graft No-Reflow

SVG-PCI requires particular caution because the graft often contains extensive, friable plaque that is readily embolized. If no-reflow develops, intracoronary administration of nitroprusside, verapamil, or adenosine may improve distal flow.

Prevention is preferable to treatment whenever possible. Direct stenting, avoidance of stent oversizing, and embolic protection when feasible are emphasized. Stenting is associated with lower restenosis rates than balloon angioplasty in SVG lesions, although the relative superiority of drug-eluting over bare-metal stents in SVG-PCI is less certain than in native coronary intervention.

Haemodynamic Support

When no-reflow causes severe ventricular dysfunction, hypotension, or shock, supportive treatment is required. In STEMI complicated by cardiogenic shock, management includes:

• Early revascularization

• Vasoactive agents

• Mechanical circulatory support when required

Rapid revascularization of the infarct-related artery is the only evidence-based treatment strategy for mortality reduction in cardiogenic shock due to MI. PCI with a drug-eluting stent in the infarct-related artery is generally preferred when feasible.

In patients with cardiogenic shock and multivessel disease, culprit-only PCI with consideration of staged revascularization is preferred over immediate multivessel PCI. Immediate treatment of nonculprit lesions increases the risk of death or renal replacement therapy and should not routinely be performed at the index procedure.

No-Reflow in the Context of Multivessel STEMI PCI

The presence of no-reflow should reinforce the principle of limiting the initial procedure to treatment of the infarct-related artery when the patient is unstable or in shock. In stable patients, significant non-infarct-related artery disease may be treated by staged PCI during the hospitalization or after discharge.

Guideline recommendations support:

• Staged PCI of a significant non-infarct artery lesion in selected haemodynamically stable STEMI patients after successful primary PCI.

• Consideration of PCI of a low-complexity non-infarct lesion during the index procedure in selected stable patients with uncomplicated culprit-vessel revascularization and normal renal function.

• Avoidance of routine non-infarct artery PCI during the index procedure in cardiogenic shock.

• Elective CABG as a reasonable option in selected stable patients with complex multivessel non-infarct disease.

There is no established preference between immediate and staged non-infarct artery PCI in stable patients. In available data, non-infarct PCI during hospitalization or after discharge produced comparable treatment effects, and the optimal timing has not been established in adequately sized superiority trials.

Guideline Recommendations

The principal recommendations relevant to prevention and treatment of no-reflow and related procedural risk are summarized below.

Complications and Prognosis

No-reflow is an important marker of procedural and myocardial risk. It is associated with:

• Approximately fivefold higher risk of periprocedural MI

• Approximately threefold higher risk of death

• Potential for severe short-term ventricular dysfunction

• Increased risk of haemodynamic collapse

• Worse short- and long-term outcomes

The prognosis is influenced by the amount of viable myocardium supplied by the affected artery, the presence of multivessel or diffuse disease, baseline stenosis severity, ventricular function, and whether cardiogenic shock develops.

In SVG-PCI, even when vasodilator treatment restores angiographic flow, the risk of death or MI remains substantially increased. This emphasizes that angiographic improvement does not necessarily eliminate the adverse prognostic implications of microvascular obstruction.

Follow-Up

The source material does not define a specific follow-up protocol after an episode of no-reflow. Follow-up should therefore be guided by the associated clinical event, particularly periprocedural MI, ventricular dysfunction, heart failure, shock, stent-related complications, or the need for staged revascularization.

Patients who have undergone PCI remain at risk for later clinical events from:

• Restenosis at the treated site

• Stent thrombosis

• Progression of atherosclerosis elsewhere

• Plaque rupture at a remote coronary site

Clinical restenosis generally appears within the first 6–9 months after PCI. Late death and MI related to plaque instability may occur at any time after the intervention. The risk is higher in patients with advanced age, reduced left ventricular function, heart failure, multivessel disease, inoperable coronary disease, or severe comorbidity.

Long-term management should include individualized antiplatelet treatment. Aspirin is generally continued indefinitely after stent implantation, with a P2Y12 antagonist ideally continued for 1 year after drug-eluting stent implantation. Longer treatment may reduce ischaemic events but increases bleeding, whereas shorter courses may be considered in patients at high bleeding risk or those requiring long-term oral anticoagulation. Any interruption of antiplatelet therapy should be coordinated with the PCI operator and limited to the shortest acceptable period.